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Case Report

Successful treatment of ibrutinib-associated central nervous
system hemorrhage with platelet transfusion support
Karen Seiter1, Michael F. Stiefel2, Jacqueline Barrientos3, Azfar Shaikh1, Nasir Ahmed1, Paul Baskind1,
Delong Liu1
1
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Abstract: Ibrutinib is a novel targeted therapy for B-cell malignancies. Hemorrhagic events were
reported in the original trials, however the mechanism of bleeding is just being elucidated. Recent studies
have demonstrated platelet dysfunction as a mechanism of bleeding. Currently we report two patients
who developed life-threatening central nervous system hemorrhage while receiving ibrutinib for chronic
lymphoid leukemia (CLL) and mantle cell lymphoma, respectively. Both patients improved rapidly after
platelet transfusions even though their platelet counts were normal or only mildly reduced at the time of
hemorrhage. We suggest that platelet transfusions can ameliorate the platelet dysfunction defect of ibrutinib
and can support the patient through the critical period until new platelet production occurs.
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Introduction
Traditional chemotherapy agents were the mainstay of
therapy for patients with chronic lymphoid leukemia (CLL)
and mantle cell lymphoma for many years. Recently, the
approval of several new agents with targeted mechanisms of
action has resulted in a paradigm shift in the treatment of
these diseases. However after the relatively rapid approval
of new drugs, the full toxicity profile may not be apparent
until a broader population of patients is exposed in the post
marketing setting.
Ibrutinib is a Bruton tyrosine kinase inhibitor (1,2) that
is approved for the treatment of mantle cell lymphoma after
at least one prior therapy (3), chronic lymphocytic leukemia
with or without a 17p deletion (4-6) and Waldenstrom’s
macroglobulinemia (7). The most common toxicities
reported are cytopenias, diarrhea, fatigue, infection,
musculoskeletal pain and bruising. Bleeding events occurred
in all of the trials but were grade 1 or 2 in most patients.
In the mantle cell lymphoma trial, bleeding occurred in
48% of patients (3), with 5% of patients having grade 3
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or higher bleeding events including subdural hematoma,
gastrointestinal bleeding, or hematuria. In the phase II CLL
trial bruising was reported in 54% of patients (4), and was
grade 3/4 in 2% of cases. In the phase III CLL trial, four
patients treated with ibrutinib had grade 3 hemorrhage and
one had grade 4 hemorrhage (5).
We recently treated two patients who developed life
threatening central nervous system (CNS) bleeding while
on ibrutinib. Both patients had a platelet count that was
above that which would be expected to result in spontaneous
bleeding. Both patients had cessation of bleeding after
administration of platelet transfusions.
Case presentation
Patient 1
The patient is a 66 years old woman who was diagnosed
with CLL in 2005 after routine blood work demonstrated
lymphocytosis. In 2012 she received 4 cycles of fludarabine,
cytoxan, rituxan (FCR) for the treatment of progressive
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Table 1 Laboratory results
Test

Normal range

Patient 1

Patient 2

4,800–10,800

165,000

500

14.0–18.0

13.8

9.9

Platelet count (/mm )

160,000–410,000

137,000

99,000

Prothrombin time (s)

9.8–12.0

10.4

10.8

Partial thromboplastin time (s)

25.0–32.0

23.7

30.5

Fibrinogen (mg/dL)

180–400

359

317

Factor VIII (%)

50–100

109

—

Ristocetin cofactor (%)

50–100

89

—

Von Willebrand multimers

Normal

Normal

—

Factor XIII

Normal

Normal

Normal

Platelet aggregation collagen (%)

66.00–98.00

59

—

Platelet aggregation ADP (%)

61.00–97.00

66

—

Platelet aggregation epinephrine (%)

61.00–93.00

65

—

Platelet aggregation ristocetin (%)

72.00–104.00

73

—

PAI-1 antigen (ng/mL)

3–72

17

—

Euglobulin lysis (s)

>60

>60

>60

70–150

87

75

3

White blood count (/mm )
Hemoglobin (g/dL)
3

Factor Xa (%)

lymphocytosis and lymphadenopathy. She was again well
until February 2015 when she developed progressive
lymphocytosis, lymphadenopathy and splenomegaly. The
patient was treated with ibrutinib 420 mg orally daily.
She was not taking any other medications. She tolerated
therapy well until November 2015 when she awoke
suddenly with intractable vomiting and confusion. The
patient was transported to a local hospital where, upon
arrival, she was unresponsive with a Glasgow coma score
of 8. She was intubated for airway protection and sedated.
A CT scan showed acute intraventricular hemorrhage with
subarachnoid blood. The patient was transferred to our
hospital for further therapy.
Upon arrival at our hospital there were no extraocular
movements and the pupils were 2 mm. The patient
localized to noxious stimuli. Sedation was held for
neurological evaluation. There was no lymphadenopathy
or hepatosplenomegaly palpable. Laboratories showed
a white blood count (WBC) of 165,000/mm 3 with 6%
neutrophils, 85% lymphocytes, 1% monocytes, and 8%
atypical lymphocytes. The hemoglobin was 13.8 g/dL, and
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the platelet count was 137,000/mm3. Peripheral blood flow
cytometry confirmed the diagnosis of CLL with 87% of
cells co-expressing CD5, CD19, CD20, CD22, and CD23
(heterogeneous). Fluorescence in situ hybridization (FISH)
subsequently demonstrated abnormalities of 6q- and 13q-.
The IGH gene variable region was unmutated. Results of
platelet aggregation studies and other coagulation tests
which were performed are summarized in Table 1. The only
abnormality detected was a mild decrease in reaction to
collagen (59%) on platelet aggregation studies.
A non-contrast CT scan of the head demonstrated
extensive intraventricular hemorrhage within the occipital
horns of the lateral ventricles, third ventricle, and
fourth ventricle. There was also a small amount of acute
subarachnoid hemorrhage within the sylvian fissures. There
was hydrocephalus with dilation of the ventricular system
and there was partial effacement of the cerebral hemispheric
sulci. A CT angiogram of the head and neck demonstrated
no evidence of intracranial aneurysm nor arteriovenous
malformation. An MRI demonstrated extensive gradient
hypointensity within the ventricular system consistent with
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acute intraventricular hemorrhage, as well as MRI findings
consistent with subarachnoid hemorrhage. Additionally
there was moderate atrophy and moderate chronic small
vessel ischemic changes.
A ventriculostomy was placed. The patient was given
single donor platelet transfusions every 6 h for a total
of 8 transfusions. The patient improved rapidly and was
discharged to a rehabilitation unit 11 days after admission.
At the time of discharge the patient was awake and alert and
fully ambulatory. She had residual deficits in the extraocular
muscle movements of the right eye and a mildly altered
affect at the time of transfer. At a 3 months follow-up visit
her modified Rankin score was 0, she had no deficits and
her speech was normal.
Patient 2
The patient was an 80-year-old man with history of
chronic obstructive pulmonary disease, atrial fibrillation on
warfarin, glaucoma, and basal cell carcinoma. He initially
presented in January 2012 with cervical lymphadenopathy.
A fine needle aspiration performed at an outside institution
showed small lymphocytic leukemia. Initially a watch and
wait approach was chosen. In July of 2015 the patient
presented with progressive lymphadenopathy and a chest
wall mass. Core biopsy of the mass demonstrated a diffuse
lymphoid infiltrate. The lymphocytes were medium to large
in size with fine chromatin. Immunohistochemistry showed
that the cells were positive for CD20, PAX-5, CD5, BCL-1,
SOX-11, BCL-2, and negative for MUM-1, CD23, BCL6, CD10. The Ki67 was 90% and FISH demonstrated the
CCND1/IGH rearrangement. The findings were consistent
with blastoid variant mantle cell lymphoma.
Due to the patient’s age and comorbities he received a
less intensive regimen than is typical for this disease. He
received 3 cycles of bendamustine and rituxan. Although
he initially demonstrated a significant reduction in the size
of the mass and lymph nodes, he had clinical progression
after the third cycle of therapy. Concurrently the patient
developed a right third cranial nerve palsy. Lumbar
puncture confirmed lymphomatous meningitis.
The patient was transferred to our care. After
discontinuation of his anticoagulation an Ommaya catheter
was placed. He received intrathecal methotrexate and was
discharged to receive treatment closer to home. The patient
was treated with ASA 81 mg daily rather than warfarin for
his high risk cardiac disease. Two weeks later the patient
began ibrutinib 420 mg orally daily concurrently with
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intrathecal methotrexate given on a weekly schedule. Three
weeks later the patient returned with severe fatigue. On
physical exam the patient was lethargic and febrile. The
complete blood count showed a WBC of 500/mm 3 with
88% neutrophils and 12% lymphocytes. The hemoglobin
was 9.9 g/dL and the platelet count was 99,000/mm3. The
LDH was 1,392 U/L, the creatinine was 1.63 mg/dL and
the uric acid was 22.3 units. Coagulation studies were
unremarkable and are listed in Table 1.
CT scan of the brain demonstrated bilateral
holohemispheric subdural collections up to 1 cm in maximal
thickness, which was hyperdense compared to CSF. The
left-sided collection had a higher density component
compatible with acute on subacute subdural hemorrhage.
The right-sided collection was favored to represent a
subacute subdural hemorrhage. There was no shift of
midline structures or hydrocephalus.
The patient was treated with intravenous antibiotics,
filgrastim, steroids and rasburicase. Single donor platelets
were given every 6 h for a total of 17 transfusions. A follow
up CT showed the expected evolution of blood products but
no further bleeding. The patient subsequently developed
pneumonia and respiratory failure and, after palliative
therapy was initiated, he expired.
Discussion
Ibrutinib is a targeted agent that is highly active against
a range of B-cell malignancies. Although bleeding events
were noted in the clinical trials, few details of the patients’
coagulation status, treatment and outcome were reported.
In vitro studies have recently demonstrated that platelet
aggregation abnormalities occur after exposure to ibrutinib.
Rigg reported that irreversible inhibition of BTK with two
ibrutinib analogs significantly decreased glycoprotein VImediated platelet activation, spreading, and aggregation
in vitro (8). Likewise, Bye demonstrated that platelets
treated with ibrutinib adhered to collagen under arterial
shear but formed unstable thrombi and that integrin
αIIbβ3 outside-in signaling was also effected in addition
to glycoprotein VI signaling (9). The authors concluded
that ibrutinib causes glycoprotein VI and integrin αIIbβ3
platelet signaling deficiencies that result in formation of
unstable thrombi and that combining ibrutinib with P2Y12
antagonists may have a detrimental effect on hemostasis.
Lipsky et al. prospectively assessed platelet function
and coagulation factors in 85 patients treated on a trial of
ibrutinib for chronic lymphocytic leukemia (10). After a
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median follow-up of 24 months the authors recorded grade
1 or 2 bleeding events in 55% of the patients. No grade 3/4
events occurred. The median time to bleeding was 49 days
and the risk of an event plateaued by 6 months. In this trial,
von Willebrand factor and factor VIII levels were often high
at baseline and then normalized on treatment. Collagen
and adenosine diphosphate induced platelet aggregation
was decreased in all patients with chronic lymphocytic
leukemia, whether on ibrutinib or not. Compared to
untreated chronic lymphocytic leukemia patients, response
to collagen showed a mild further decrement on ibrutinib,
while response to adenosine diphosphate improved. The
authors concluded that both disease and treatment-related
factors influenced the risk of bleeding. In a smaller clinical
study, Levade et al. demonstrated that ibrutinib selectively
inhibited platelet signaling and functions downstream of the
collagen receptor glycoprotein VI and strongly affected firm
platelet adhesion on von Willebrand factor under arterial
flow (11). The addition of 50% untreated platelets was
sufficient to efficiently reverse the effects of ibrutinib, and
platelet functions recovered after treatment interruption
as physiological platelet renewal occurred. Kamel et al.
also noted that 23 patients receiving ibrutinib all had
reductions in collagen-mediated platelet aggregation, and
that there was a significant association between the degree
of inhibition and the occurrence of clinical bleeding or
bruising (12).
Our first patient had no major risk factors for CNS
bleeding and developed life threatening hemorrhage
without any warning. The only abnormality found was a
very mild reduction in platelet aggregation in response
to collagen. Our second patient multiple risk factors for
hemorrhage. He had a recent neurosurgical procedure as
well as lymphomatous meningitis. He also had a history of
atrial fibrillation and was on low dose aspirin at the time of
his hemorrhage. Due to the reports of platelet dysfunction
we treated both of our patients with platelet transfusions,
even though one had a normal platelet count and the other
had only a mild reduction in platelet count. The first patient
had a dramatic improvement in her clinical condition
after the infusions. The second patient had resolution of
bleeding, but opted for comfort care after he developed
pneumonia and he subsequently expired from causes
unrelated to the hemorrhage.
It is impossible to know if the resolution of bleeding was
directly related to the platelet transfusions administered or
was just due to clearance of ibrutinib and production of new
platelets by the patient. However, in view of the favorable
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bleeding outcomes, we propose that this is a reasonable
approach to the patient who has life threatening bleeding
while on ibrutinib.
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